Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2026-01-01 @ 1:34 AM
Study NCT ID:
NCT06942403
Status:
COMPLETED
Last Update Posted:
2025-04-24
First Post:
2025-04-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
In-use Tolerance and Efficacy Study Under Dermatological Control of an Anti-aging Cream (Split Face) Post Facial Superficial Rejuvenation Procedures, After re Epidermization
Sponsor:
Pierre Fabre Dermo Cosmetique
Organization:
Study Overview
Official Title:
In-use Tolerance and Efficacy Study Under Dermatological Control of an Anti-aging Cream (Split Face) Post Facial Superficial Rejuvenation Procedures, After re Epidermization
Status:
COMPLETED
Status Verified Date:
2025-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to assess the dermatological tolerance of the investigational product "Crème visage Product code: RV4983A / Formula code: LA3365" after 95 days for subjects post peeling and LASER and 176 days for subjects post injections of once daily use at the evening on the half face, under normal conditions of use, on 66 subjects.
This study will be conducted as a national, monocentric, open trial.
Planning of the visits:
* Visit 1: Inclusion (Day 1) - The subjects undergo their procedure (peeling, LASER or injections).
* Home application of the associated product 1 period: Day 1 to Day 7
* Visit 2: intermediate visit (Day 8) subjects received investigational product and associated product 2;
* Visit 3, 4, and 5: Intermediate visit (Day 37, Day 66 and Day 95\*),
\*the final visit for the subjects post peeling and LASER
* Visit 6\*\*: End of study (Day 176), \*\* for subjects post injections
This study will be conducted as a national, monocentric, open trial.
Planning of the visits:
* Visit 1: Inclusion (Day 1) - The subjects undergo their procedure (peeling, LASER or injections).
* Home application of the associated product 1 period: Day 1 to Day 7
* Visit 2: intermediate visit (Day 8) subjects received investigational product and associated product 2;
* Visit 3, 4, and 5: Intermediate visit (Day 37, Day 66 and Day 95\*),
\*the final visit for the subjects post peeling and LASER
* Visit 6\*\*: End of study (Day 176), \*\* for subjects post injections
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: